Allogeneic Transplant Following Brentuximab Vedotin Treatment (2011 ASH Conference)



Allogeneic stem cell transplant (allo-SCT) for relapsed or refractory lymphoma is often limited by the amount of residual tumor burden following cytoreductive therapy. Clinical Director of the Division of Hematologic Oncology Craig Moskowitz discusses recent phase II trials where brentuximab vedotin induced objective responses in 75 percent of patients with Hodgkin lymphoma and 86 percent of patients with systemic ALCL.

Results suggest that brentuximab vedotin may be an option for reducing tumor burden to facilitate a consolidative allo-SCT and warrants further study.